The added effect of thioridazine in the treatment of drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 12, 2012, Pages 1706-1708

  Amaral, Leonard ^a   Udwadia, Zarir ^b   Abbate, Eduardo ^c   Van Soolingen, Dick ^d  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; CHLORPROMAZINE; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PHENOTHIAZINE; RIFAMPICIN; SILA 421; SUTEZOLID; THIORIDAZINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EX VIVO STUDY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LETTER; LOW DRUG DOSE; MACROPHAGE; MALNUTRITION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; TUBERCULOSIS;

EID: 84870330683     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0616     Document Type: Letter

References (21)

1. Grosset J H, Singer T G, Bishai W R. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.
2. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 2007; 59: 1237-1246.
3. Amaral L, Viveiros M, Kristiansen J E. 'Non-antibiotics': alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006; 7: 887-891.
4. Barr R G, Diez-Roux A V, Knirsch C A, Pablos-Méndez A. Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984-1992. Am J Public Health 2001; 91: 1487-1493.
5. Crowle A J, Douvas G S, May M H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38: 410-419.
6. Amaral L, Kristiansen J E, Abebe L S, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049-1053.
7. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree M J, van Soolingen D. In vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents 2009; 34: 190-191.
8. Ordway D, Viveiros M, Leandro C, et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-922.
9. Martins M, Viveiros M, Kristiansen J E, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007; 21: 771-775.
10. van Soolingen D, Hernandez-Pando R, Orozco H, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS ONE 2010; 5 pii: e12640.
11. Martins M, Viveiros M, Ramos J, et al. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int J Antimicrob Agents 2009; 33: 479-482.
12. Udwadia Z F, Amale R A, Abjani K K, Rodriguez C. Totally drug resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
13. Udwadia Z F, Sen T, Pinto L M. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov 2011; 6: 88-91.
14. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-477.
15. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376-380.
16. Reeves E P, Lu H, Jacobs H L, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 2002; 416: 291-297.
17. Machado D, Couto I, Perdigão J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012; 7(4): e34538.
18. Steenwinkel J E, Ten Kate M T, de Knegt G J, et al. Consequences of non-compliance on therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype. Antimicrob Agents Chemother 2012; 56: 4937-4944.
19. Devaux I, Manissero D, Fernandez de la Hoz K, Kremer K, van Soolingen D; EuroTB Network. Surveillance of extensively drugresistant tuberculosis in Europe, 2003-2007. Euro Surveill 2010; 15. pii: 19518.
20. Rajbhandary S S, Marks S M, Bock N N. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1012-1016.
21. Amaral L, Molnar J. Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis (TDR TB). Expert Rev Anti-Infect Ther 2012; 10: 869-873.